Reuters top ten news stories delivered to your inbox each day.
You are here:
Business & Finance
The Great Debate
Do More With Reuters
Make Reuters My Homepage
Support (Customer Zone)
About Thomson Reuters
Nobel prize-winning medical research long and costly
Mon Oct 5, 2009 8:43pm EDT
Email | Print |
| Reprints | Single Page
By Peter Henderson
SAN FRANCISCO (Reuters) - The Nobel-winning medical science that points the way to a cancer cure was sparked by curiosity, not business sense, a new laureate said on Monday.
Elizabeth Blackburn won the Nobel prize for medicine together with Carol Greider and Jack Szostak for work on the existence and nature of telomerase, an enzyme that helps prevent the fraying of chromosomes and is core to new work on aging and cancer.
Federal research grants made the work possible, and that money is becoming more important as the California public education system which nurtured the science struggles with budget cuts that will probably reduce the wages of Blackburn and her colleagues.
Now a professor of biology and physiology at the University of California, San Francisco, Blackburn's federal grant application had proposed understanding how the ends of the chromosomes worked.
"I was just following my nose," she told a news conference after the announcement of her prize by the Nobel committee in Stockholm. "That would look pretty bad in a business plan," she said, noting that basic research is long and costly.
Blackburn's work in the field dates to the late 1970s, and about three decades later a therapy based on the enzyme is in trials by biotech firms Merck and Geron.
Now the University of California system is chopping salaries and raising the fees that have made it unusually affordable, raising questions over whether Blackburn and her colleagues will face wage cuts for future research.
"Get a Nobel prize, have a pay cut," quipped Blackburn. "It sort of breaks my heart to see it being under attack."
NO QUICK PROFIT
Blackburn's San Francisco lab on Monday was filled with fluorescent proteins, cleansing solutions and young scientists asking basic questions that may not cure anything soon, but could be the first step to a drug years away from development.
Her research has federal backing and President Barack Obama last week earmarked $5 billion from recent stimulus funding for medical research that might not "lend itself to quick profit."
So Blackburn's lab is still full of "crazy" questions, in the words of doctoral student Beth Cimini, 23, who was filling a syringe with a blue liquid. The work is part of a plan to put fluorescent "tags" on a protein and see how it reacts with telomeres, as the ends of the chromosomes are called.
"I went to Liz and said ... 'It might be wacky, but can we try it'?" said Cimini, who added that results suggest her hunch may not be "entirely crazy."
Closer ties between academia and corporations on basic research might provide a way forward in the future.
"The old paradigm needs to be revamped," said Sam Hawgood, dean of the University of California San Francisco School of Medicine, who says star researchers may be able to attract corporate backing even for basic science. Continued...
View article on single page
Also On Reuters
Analysis: "Government Sachs" lets one well run dry
Video: China suitmaker wins Warren Buffett's business
Full Coverage: Reuters Wealth Management Summit
More International News
North Korea says ready to return to nuclear talks
Gates blames past lack of troops for Taliban edge
Suicide bomber kills 5 at Pakistani U.N. office
Quake-hit Indonesian city sprayed to stop disease
Suicide bomber kills at least 6 at Iraqi funeral
More International News...
A selection of our best photos from the past 24 hours. Slideshow
Most Popular on Reuters
Gulf in talks on replacing U.S.$ for oil: report
RPT-GLOBAL MARKETS-Dollar skids on Gulf oil report; stocks up
U.S. Senate panel awaits report before health vote
Apple, citing climate, tells U.S. Chamber iQuit
Q+A: Has the back of the Pakistani Taliban been broken?
Italian scientist reproduces Shroud of Turin
Weak dollar, oil turnaround lift US gold futures
Letterman says wife "horribly hurt" by sex scandal
Conde Nast magazines shut as review bites
Australia central bank raises rates, more expected
Most Popular Articles RSS Feed
Trio of Americans win Nobel Medicine
China suitmaker wins Buffett biz
No Lycra please, we're British
California fire threatens resort
Rescue teams arrive in Indonesia
China-N.Korea in new courtship
Greece's PM-elect offers recovery
Samoan tsunami dead mourned
Health workers get H1N1 vaccine
Kim and Wen's night at the opera
Most Popular Videos RSS Feed
Help and Contact Us |
Advertise With Us |
Journalism Handbook |
Site Index |
Thomson Reuters Corporate:
Professional Products |
Professional Products Support |
About Thomson Reuters |
Latin America |
United Kingdom |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.